TY - JOUR
T1 - Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes
T2 - Findings from the Apolipoprotein Mortality Risk (AMORIS) cohort
AU - Shackshaft, Lydia
AU - Van Hemelrijck, Mieke
AU - Garmo, Hans
AU - Malmström, Håkan
AU - Lambe, Mats
AU - Hammar, Niklas
AU - Walldius, Göran
AU - Jungner, Ingmar
AU - Wulaningsih, Wahyu
PY - 2017/3/6
Y1 - 2017/3/6
N2 - Background: Different etiological pathways may precede development of specific breast cancer subtypes and impact prevention or treatment strategies. We investigated the association between gamma-glutamyl transferase (GGT) and development of specific breast cancer subtypes based on oestrogen receptor (ER), progesterone receptor (PR) and HER2 status. Methods: We included 231,283 cancer-free women in a Swedish cohort. Associations between GGT and breast cancer subtypes were investigated with nested case-control and case-case analyses. We used logistic regression models to assess serum GGT in relation to breast cancer subtype, based on individual and combined receptor status. Results: Positive associations were found between serum GGT and development of ER+, ER- and PR+ breast cancers compared to controls (odds ratio (OR) 1.14 (95% confidence interval (CI) 1.08-1.19), 1.11 (1.01-1.23) and 1.18 (1.12-1.24), respectively) and of ER+/PR+ tumours. We found inverse associations between GGT levels and PR- breast cancers compared to PR+ (OR 0.87 (0.80-0.95)), between ER+/PR- tumours compared to ER+/PR+ tumours and between ER-/PR-/HER+ compared to ER+/HER2 or PR+/HER2 tumours (OR 0.55 (95% CI 0.34-0.90). Conclusion: The observed associations between pre-diagnostic serum GGT and different breast cancer subtypes may indicate distinct underlying pathways and require further investigations to tease out their clinical implications.
AB - Background: Different etiological pathways may precede development of specific breast cancer subtypes and impact prevention or treatment strategies. We investigated the association between gamma-glutamyl transferase (GGT) and development of specific breast cancer subtypes based on oestrogen receptor (ER), progesterone receptor (PR) and HER2 status. Methods: We included 231,283 cancer-free women in a Swedish cohort. Associations between GGT and breast cancer subtypes were investigated with nested case-control and case-case analyses. We used logistic regression models to assess serum GGT in relation to breast cancer subtype, based on individual and combined receptor status. Results: Positive associations were found between serum GGT and development of ER+, ER- and PR+ breast cancers compared to controls (odds ratio (OR) 1.14 (95% confidence interval (CI) 1.08-1.19), 1.11 (1.01-1.23) and 1.18 (1.12-1.24), respectively) and of ER+/PR+ tumours. We found inverse associations between GGT levels and PR- breast cancers compared to PR+ (OR 0.87 (0.80-0.95)), between ER+/PR- tumours compared to ER+/PR+ tumours and between ER-/PR-/HER+ compared to ER+/HER2 or PR+/HER2 tumours (OR 0.55 (95% CI 0.34-0.90). Conclusion: The observed associations between pre-diagnostic serum GGT and different breast cancer subtypes may indicate distinct underlying pathways and require further investigations to tease out their clinical implications.
KW - Breast cancer
KW - GGT
KW - Glucose
KW - Prospective study
KW - Triglycerides
UR - http://www.scopus.com/inward/record.url?scp=85014521350&partnerID=8YFLogxK
U2 - 10.1186/s13058-017-0816-7
DO - 10.1186/s13058-017-0816-7
M3 - Article
AN - SCOPUS:85014521350
SN - 1465-542X
VL - 19
JO - Breast Cancer Research
JF - Breast Cancer Research
IS - 1
M1 - 22
ER -
